Docosahexaenoic acid (DHA) is an important component of neural membranes and is present in 30-40% of the phospholipids in the gray matter of cerebral cortex and photoreceptor cells in the retina. It mediates its molecular and cellular effects not only through regulation of physicochemical properties such as membrane fl uidity, permeability and viscosity in synaptic membranes, but also via modulation of neurotransmission, gene expression, and activities of enzymes, receptors and ion channels ( Fig. 1) (Farooqui, 2009) . These processes are closely associated with activation of signaling pathways that sustain synaptic function and neuronal survival (Oster and Pillot, 2010) .
BENEFICIAL EFFECTS OF DOCOSAHEXAENOIC ACID ON THE BRAIN
Docosahexaenoic acid (DHA) is an important component of neural membranes and is present in 30-40% of the phospholipids in the gray matter of cerebral cortex and photoreceptor cells in the retina. It mediates its molecular and cellular effects not only through regulation of physicochemical properties such as membrane fl uidity, permeability and viscosity in synaptic membranes, but also via modulation of neurotransmission, gene expression, and activities of enzymes, receptors and ion channels ( Fig. 1) (Farooqui, 2009) . These processes are closely associated with activation of signaling pathways that sustain synaptic function and neuronal survival (Oster and Pillot, 2010) .
PUFAs including DHA have anti-oxidative stress, anti-infl ammation and anti-apoptosis effects leading to neuroprotection in aged, damaged or Alzheimer's disease brain ( Fig. 1 ) (Farooqui et al., 2007; Farooqui, 2009 ). Anti-oxidant and antiinfl ammatory actions of DHA are associated with reduction in cellular levels of reactive species, pro-infl ammatory mediators and nitrite levels, maintaining higher GSH levels and increasing anti-oxidant enzyme activities (Kim and Chung, 2007) . DHA attenuates brain necrosis after hypoxic ischemic injury by modulating membrane biophysical properties and maintaining Docosahexaenoic acid (DHA) is the major polyunsaturated fatty acid (PUFA) in the brain and a structural component of neuronal membranes. Changes in DHA content of neuronal membranes lead to functional changes in the activity of receptors and other proteins which might be associated with synaptic function. Accumulating evidence suggests the benefi cial effects of dietary DHA supplementation on neurotransmission. This article reviews the benefi cial effects of DHA on the brain; uptake, incorporation and release of DHA at synapses, effects of DHA on synapses, effects of DHA on neurotransmitters, DHA metabolites, and changes in DHA with age. Further studies to better understand the metabolome of DHA could result in more effective use of this molecule for treatment of neurodegenerative or neuropsychiatric diseases.
www.biomolther.org be taken in the diet. Common sources of n-3 PUFA include fi sh oils and some plant oils such as fl axseed oil and algal oil, which contain precursors of DHA, namely alpha-linolenic acid (α-LNA). After uptake, n-3 PUFAs enter the brain and are incorporated at the sn-2 position of glycerol moiety of phospholipids including plasmalogens and phosphatidylserine. DHA is released through the action of plasmalogen-selective phospholipase A 2 (PlsEtn-PLA 2 ) and calcium-independent phospholipase A 2 (iPLA 2 ) (Farooqui et al., 2003; Strokin et al., 2003; Rosa and Rapoport, 2009; Farooqui, 2010a) . Dietary supplementation with 10 and 40 mg/kg/day of DHA for 30 days results in signifi cantly increased DHA serum levels of 123 and 175% over baseline respectively (Bailes and Mills, 2010) . DHA concentrations of 17.6, 11.4, and 7.14 μmol/g are found in the brains of rats on diets with high DHA and α-LNA content, an n-3 PUFA adequate diet containing 4.6% α-LNA but no DHA, or an n-3 PUFA defi cient diet containing 0.2% α-LNA and no DHA, respectively (Rapoport and Igarashi, 2009 ).
Incorporation of DHA at synapses
The transport of fatty acids such as DHA and arachidonic acid (AA) across the blood-brain barrier and other non-neural cellular membranes most likely occurs through passive diffusion. DHA and AA transport is facilitated by a number of membrane-associated and cytoplasmic proteins. These include membrane proteins fatty acid translocase (FAT/CD36), plasma membrane fatty acid-binding protein (FABP) and fatty acid-transport protein (FATP) (Utsunomiya et al., 1997) . FABP binds to a broad range of saturated and unsaturated long chain free fatty acids, including DHA, eicosapentaenoic acid (EPA), and AA. Rat pheochromocytoma (PC12) cells exposed to nerve growth factor exhibit high FABP expression (Liu et al., 2008) .
DHA is a major structural component of gray matter neuronal membranes. At the subcellular level, the highest concentration of DHA is found in synaptic membranes followed by mitochondria and microsomes (Scott and Bazan, 1989) . DHA-containing ethanolamine phosphoglyceride species accumulate in response to n-3 fatty acid feeding, suggesting a causal relationship between two events (Kitajka et al., 2002) . The developing brain or hippocampal neurons take up DHA and incorporates it into membrane phospholipids especially phosphatidylethanolamine, resulting in neurite outgrowth, synaptogenesis and neurogenesis. Exposure to n-3 PUFAs enhances synaptic plasticity by increasing synaptic protein expression, dendritic spine density, long-term potentiation and neurogenesis in the hippocampus for learning and memory processing (Fig. 1) .
DHA is mainly found in ethanolamine plasmalogen (PlsEtn) and phosphatidylserine (PtdSer), whereas the majority of AA is incorporated into phosphatidylcholine (PtdCho). From PlsEtn and PtdSer, DHA is released by the action of PlsEtn-PLA 2 and PtdSer hydrolyzing PLA 2 , respectively (Farooqui, 2009; Farooqui, 2010a) . DHA is necessary for the proper formation of phospholipids which are an essential component of the cell membrane. Most phospholipids contain glycerol esterifi ed with saturated and unsaturated fatty acids at sn-1 and sn-2 position respectively. Brain phospholipid synthesis requires three circulating compounds: fatty acids (DHA or AA), uridine and choline (Wurtman et al., 2010) . Animals given all three nutrients develop increased levels of brain phosphatides and proteins that are concentrated in synaptic membranes (e.g. PSD-95, synapsin-1), improved cognition and enhanced neurotransmitter release. These nutrients work by increasing the substrate-saturation of low-affi nity enzymes that synthesize the phosphatides (Wurtman et al., 2009a) . Nutritional studies indicate that the phospholipid content of synaptic plasma membrane is signifi cantly increased in DHA-fed rats (Shahdat et al., 2004) .
Release of DHA at synapses
PlsEtn-PLA 2 releases DHA from PlsEtn (Farooqui et al., 2003; Farooqui, 2010a) . In addition, iPLA 2 releases DHA from the sn-2 position of glycerol moiety with the generation of lysophospholipid. Cellular studies suggest that AA and DHA release depend on Ca 2+ . The source of Ca 2+ for activation of cPLA 2 is largely extracellular, whereas Ca 2+ released from the endoplasmic reticulum can activate iPLA 2 by a number of mechanisms (Rosa and Rapoport, 2009 ). Imaging mass spectrometry shows not only a prominent increase of DHA-containing PtdCho in the gray matter but also insuffi cient membrane remodeling in iPLA 2 β knockout mice, a model of infantile neuroaxonal dystrophy (Beck et al., 2011) . The released DHA is metabolized to resolvins and neuroprotectins by 15-lipoxygenase (Bazan, 2005) . These mediators are collectively known as docosanoids. They have anti-infl ammatory and anti-apoptotic properties and are involved in neuroprotection. In addition, docosanoids have anti-thrombotic, anti-arrhythmic, hypolipidemic, and vasodilatory effects (Farooqui, 2009 ).
EFFECTS OF DHA ON SYNAPSES

Neurite outgrowth
Treatment of PC12 cells for 3 days with n-3 PUFA significantly enhances neurite length without affecting the number of neurites (Shrivastava et al., 2005) . DHA also induces neurite outgrowth in cells beginning as early as 2 h post-DHA supplementation and throughout differentiation. Transcripts of the neurogenesis markers Egr3 and PC3 are signifi cantly elevated within 0.5 to 1 h of DHA supplementation (Dagai et al., 2009) . DHA promotes differentiation and neurite outgrowth of neurons derived from mouse embryonic stem cells and increases proliferation of cells undergoing differentiation into neuronal lineages (He et al., 2009) . Conversely, hippocampal neurons from DHA-depleted fetuses show reduced neurite growth and synaptogenesis (Cao et al., 2009) . DHA is one of the most potent inducers of neurite outgrowth among fatty acids surveyed, on expression of a marker of axonal growth, growth-associated protein-43 (GAP-43). Exposure of human neuroblastoma SH-SY5Y cells to DHA increases the percentage of cells with longer neurites, associated with protein tyrosine phosphatase inhibition, mitogen-activated protein kinase/ ERK kinase phosphorylation and sequentially ERK1/2 phosphorylation. In contrast, no effect was found after supplementation with AA, oleic acid or docosapentaenoic acid (Calderon and Kim, 2004; Wu et al., 2009) .
Oral supplementation with DHA increases number of dendritic spines in the adult gerbil hippocampus, particularly when animals are co-supplemented with a uridine source, uridine-5'-monophosphate, which increases brain levels of the rate-limiting phosphatide precursor cytidine triphosphate (Sakamoto et al., 2007) . Uridine and DHA supplementation in rodents also enhances dendritic spine levels and cognitive functions. Moroever, DHA treatment increases the expression of biochemical markers for neurites, neurofi lament-M and neurofi lament-70 (Wurtman et al., 2009b) .
SNARE complex and other synaptic proteins
DHA facilitates the formation of v-SNARE/t-SNARE complex, necessary for fusion of synaptic vesicles and plasma membranes and neurite outgrowth-dependent plasticity (Walczewska et al., 2011) . DHA affects the expression of the SNARE complex protein syntaxin-3 (Sharma et al., 2010) . Treatment with DHA increases co-localization and interaction of SNAP-25 and syntaxin-3, and delivery of membrane and synaptic membrane biogenesis (Mazelova et al., 2003) . Voluntary exercise potentiates the effects of a 12-day DHA dietary supplementation regimen on increasing the levels of syntaxin-3 and GAP-43 in the adult rat hippocampus (Chytrova et al., 2010) .
Increased DHA (34%) and decreased AA (-23%) in brain fatty acid concentrations are detected after consumption of DHA-enriched diet. Compared to the n-3 PUFA-defi cient diet, consumption of DHA results in increased spontaneous excitatory postsynaptic current frequency (Arsenault et al., 2011) . Defi ciency in DHA leads to reduced levels of the NR2B subunit of the NMDA receptor in rats (Sharma et al., 2010) . Reduction of dietary n-3 PUFA in an Alzheimer's mouse model results in 80-90% losses of the p85alpha subunit of phosphatidylinositol 3-kinase and the postsynaptic actin-regulating protein drebrin. The loss of postsynaptic proteins is associated with increased oxidation, without concomitant loss of neurons or presynaptic protein (Calon et al., 2004) .
G-protein coupled receptor 40 (GPR40) is expressed ubiquitously in the human brain and pancreas, and is a seventransmembrane receptor which is activated by DHA. DHA-induced neuronal differentiation, neurite growth and branching of adult rat stem cells are enhanced by increased GPR40 expression, suggesting that the DHA/GPR40 signaling pathway is related to adult neurogenesis in the hippocampus (Ma et al., 2010) .
EFFECTS OF DHA ON NEUROTRANSMITTERS
Glutamate
DHA enhances glutamatergic synaptic activities with concomitant increases in synapsin and glutamate receptor subunit expression in hippocampal neurons (Kim et al., 2011b) . Spontaneous synaptic activity is signifi cantly increased due to enhanced glutamatergic activity in DHA-supplemented neurons. On the other hand, lack of DHA results in inhibition of synaptogenesis, decreases in synapsins and glutamate receptor subunits, and impairment of long-term potentiation in hippocampal neurons (Cao et al., 2009) . DHA modulates the activities of glutamate transporters (GLT1, GLAST, and EAAC1). DHA stimulates GLT1 and EAAC1 through a mechanism that requires extracellular Ca 2+ , CaM kinase II, and protein kinase C but not protein kinase A. In contrast, the inhibitory effect of DHA on GLAST does not require extracellular Ca 2+ and does not involve CaM kinase II (Berry et al., 2005; Farooqui, 2010b) . DHA may also reduce uptake of the neurotransmitter d-[ 3 H] aspartate by cultured astrocytes and cortical membrane suspensions, while AA does not. This effect is also found in astrocytes enriched with the anti-oxidant, α-tocopherol, suggesting that it is not due to oxidation products of DHA. Reduction of d-[
3 H] aspartate uptake by DHA does not involve any change in the expression of membrane-associated astroglial glutamate transporters (GLAST and GLT-1), indicating that DHA reduces the activities of the transporters. In contrast to inhibition induced by free-DHA, membrane-bound DHA has no effect on d-[ 3 H] aspartate uptake (Grintal et al., 2009) .
GABA
DHA inhibits GABA receptor-mediated responses in cultured neural cells in a concentration and time-dependent manner. It is shown that the γ subunit is essential for the potentiation of GABA induced Cl − channel activity and effect on desensitization kinetics of the GABAA receptor (Nabekura et al., 1998) . DHA accelerates desensitization after the peak of the GABA-induced current, potentiates the peak amplitude of GABA response, and gradually suppresses the peak amplitude of GABA response (Nabekura et al., 1998) . It is suggested that the effect of DHA on GABA receptor is due to the effect on the lipid microenvironment for the GABA receptors (Nabekura et al., 1998) .
Dopamine
Chronic n-3 PUFA defi ciency alters the internalization of dopamine (DA) in the storage pool of the frontal cortex (Zimmer et www.biomolther.org al., 1998). Diet-induced defi cits in brain DHA lead to redistribution of DA vesicles in presynaptic terminals, greater basal extracellular DA concentrations and defi cits in tyramine-induced elevations in extracellular DA concentrations in the prefrontal cortex and ventral striatum (Chalon, 2006) . Moreover, mice on a DHA defi cient diet show augmented amphetamine-induced locomotor sensitization, and this response is associated with alterations in the mesolimbic DA pathway (McNamara et al., 2008) . These observations suggest that alterations in synaptic membrane DHA have an impact on DA synaptic neurotransmission and plasticity (Farooqui, 2010b) .
Serotonin
N-3 PUFA defi ciency results in changes in the vesicular pool of serotonin (5-HT) as well as DA, thus inducing several regulatory processes such as modifi cation of cerebral receptors in specifi c brain areas (Chalon, 2006) . Chronic n-3 PUFA dietary defi ciency induces changes in synaptic levels of 5-HT under basal conditions and after stimulation with fenfl uramine. Higher levels of basal 5-HT release and lower levels of fenfl uramine stimulated 5-HT release are found in PUFA-defi cient than control rats. These neurochemical modifi cations can be reversed by supply of balanced diet at birth or during the fi rst 2 weeks of life, through maternal milk -however, they persist if the balanced diet is given after weaning (Kodas et al., 2004) .
Noradrenaline
Both a high membrane DHA content and free DHA in the medium enhance the release of [
3 H]-noradrenaline in cultured SH-SY5Y cells (Mathieu et al., 2010 ).
Acetylcholine
Plasma [
3 H] DHA incorporation into synaptic membrane phospholipids of the rat brain is selectively increased after cholinergic activation (Jones et al., 1997) . DHA defi ciency produces a 10% decrease in muscarinic receptor binding, although acetylcholinesterase activity and the vesicular acetylcholine transporter are not affected (Aïd et al., 2003) .
Endocannabinoids
The CB1 receptor which responds to endocannabinoids are uncoupled from their effector G (i/o) proteins in n-3 PUFA defi cient mice (Lafourcade et al., 2011) .
Other molecules
DHA supplementation elevates brain DHA content, normalizes levels of brain-derived neurotrophic factor (BDNF), synapsin I, cAMP responsive element-binding protein (CREB), and CaMKII and improves learning ability in rats after traumatic brain injury (Wu et al., 2011) . DHA defi cit induces downregulation of brain glucose transporter protein expression, resulting in decreased glucose utilization in the cerebral cortex of DHA-defi cient rats (Pifferi et al., 2005) . DHA also interacts with the peroxisome proliferator activated receptors (PPAR), sterol regulatory element binding protein (SREBP), and carbohydrate response element binding protein (ChREBP) (de Urquiza et al., 2000; Lengqvist et al., 2004) . These infl uence the activities of signal transduction processes during neurotransmission.
DHA limits amyloid-or oxidative stress-induced damage and cognitive defi cits in an amyloid precursor protein (APP) transgenic mouse model of Alzheimer's disease (Cole et al., 2005) . In addition, levels of the dendritic protein, drebrin are signifi cantly increased in the hippocampus of APP transgenic mice on a DHA-rich diet. These fi ndings support the notion that increased DHA consumption may play a role in reducing brain insults in Alzheimer's disease patients (Perez et al., 2010) .
DHA metabolites
DHA metabolism to DEA leads to neurite growth, synaptogenesis, synaptic protein expression, and enhanced glutamatergic synaptic function (Kim et al., 2011a) . DHA is converted to DEA by fetal mouse hippocampal neuronal cultures and hippocampal homogenates, and DEA is present endogenously in the mouse hippocampus. Furthermore, DEA stimulates neurite growth and synaptogenesis at substantially lower concentrations than DHA, and it enhances glutamatergic synaptic activities with concomitant increases in synapsin and glutamate receptor subunit expression in the hippocampal neurons (Kim et al., 2011b) . The actions of DHA may also mediated by its metabolites, resolvins D1, D2, D3, D4, D5, D6, neuroprotectin D1 (NPD1), and N-docosahexaenoylethanolamide (DEA) (Fig. 2) . The resolvins D1-D6 induce anti-infl ammatory activity. They reduce neutrophil infi ltration; paw edema and proinfl ammatory cytokine expression. Similarly, NPD1 elicits potent anti-infl ammatory actions and prohomeostatic bioactivity. It also produces anti-angiogenic effects and induces cell survival (Bazan et al., 2011) . Calcium ionophore A-23187-induced synthesis of NPD1 in human ARPE-19 cells is enhanced by DHA. Under these conditions, there is a time-dependent release of endogenous free DHA followed by NPD1 formation. NPD1 potently counteracts H 2 O 2 /tumor necrosis factor alpha oxidative-stress-triggered apoptotic DNA damage (Mukherjee et al., 2004) .
Changes in DHA with age
Aging not only reduces levels of n-3 PUFAs but also decreases neural membrane plasticity. Decline in n-3 PUFAs with age is accompanied by loss of learning and memory and ageing is also associated with decreases in the GluR2 and NR2B subunits of glutamate receptors in the prefrontal cortex, hippocampus and striatum. These decreases can be fully reversed by n-3 PUFA supplementation (Dyall et al., 2007) . n-3 PUFA supplementation reverses age-related changes and maintains learning and memory performance in aged rats (Farooqui et al., 2007; Su, 2010) . Multiple mechanisms of action can be associated with the neuroprotective effects of DHA, including anti-oxidant properties and activation of distinct cell signaling pathways. Dietary supplementation of DHA normalizes the age-related decrease in unsaturation index, reduces the levels of AA-containing phospholipids in both young and aged animals, and gives rise to production of new phosphatidylserine and phosphatidylinositol species (Little et al., 2007) .
Further studies to better understand the metabolome of DHA could result in more effective use of this molecule for treatment of neurodegenerative or neuropsychiatric diseases.
